Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzheng Tongluo Formula is a traditional Chinese medicine (TCM) herbal prescription used primarily for the treatment of idiopathic pulmonary fibrosis (IPF) and is under investigation for gastric precancerous lesions. The formula consists of multiple herbs and acts by inhibiting lung fibroblast activation, reducing inflammatory responses, promoting autophagy, and alleviating fibrosis. Mechanistically, its effects are mediated via inhibition of the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway. Preclinical studies have shown that it can alleviate IPF injury in animal models by these mechanisms[1]. Clinical trials are ongoing to explore its efficacy in gastric precancerous lesions[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuzheng Tongluo Formula.